UOS and Eli Lilly strengthen partnership in public health research

The meeting was held at the Research Institute for Medical and Health Sciences (RIMHS) and gathered eminent academics, scientists, and researchers from both sides.

Joint efforts to tackle public health challenges

Representing the university were Professor Rifaat Akram Hammoudi, Acting Director of the Institute; Dr Wafaa Al Nakhi, Director of the Centre for Excellence in Public Health; and Professor Farah Naja from the College of Health Sciences, along with members of the Health Promotion Research Group.

The Lilly delegation included Dr Anna Koroleva, Medical and Cardiometabolic Lead for the Middle East; Tania Tannous, Associate Director for Public and Government Affairs, Value, and Access for the Middle East and North Africa; and Dr Dianne Dao, Regional Director for Real-World Evidence and Medical Research.

Discussions focused on the increasing public health issues caused by non-communicable diseases such as obesity and diabetes, highlighting the importance of evidence-based and applied research to develop effective prevention and treatment strategies in accordance with the UAE’s national health priorities.

Commitment to long-term partnership

Both parties reaffirmed their commitment to establish a long-term strategic partnership that will improve research capabilities, promote educational exchange, and support the creation of innovative public health solutions throughout the UAE.

The partnership will utilise Lilly’s pharmaceutical expertise and UOS’s academic and research excellence to develop impactful, community-driven programmes aimed at enhancing health outcomes and quality of life.

Through these initiatives, the University of Sharjah continues to strengthen its position as a regional leader in scientific research, contributing to the progress of healthcare systems and public health policy in the Emirates and beyond.